| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 03/27/2002 | EP1189623A2 Method and composition for inhibiting cardiovascular cell proliferation |
| 03/27/2002 | EP1189618A1 Thrombin inhibitors |
| 03/27/2002 | EP1189613A1 Method for the treatment of neurological or neuropsychiatric disorders |
| 03/27/2002 | EP1189609A1 Cxcr-4 receptor antagonists - thrombopoietin mimetics |
| 03/27/2002 | EP1189605A2 High molecular weight primary aliphatic alcohols obtained from beeswax and pharmaceutical use thereof |
| 03/27/2002 | EP1189604A2 Zinc ionophores as anti-apoptotic agents |
| 03/27/2002 | EP1189595A1 Ophthalmic compositions in form of aqueous gels |
| 03/27/2002 | EP1189583A1 Indole derivatives |
| 03/27/2002 | EP1007534A4 Bh3 interacting domain death agonist |
| 03/27/2002 | EP0946562B1 PYRROLO[3,4-d]PYRIMIDINONE DERIVATIVES AND THEIR USE AS IMMUNOSUPPRESSANTS |
| 03/27/2002 | EP0946503B1 Nitromethylthiobenzene derivatives as inhibitors of aldose reductase |
| 03/27/2002 | EP0942719B1 (r)-verapamil as a medicament for the treatment of angina |
| 03/27/2002 | EP0865421B1 Arylethanolamine derivatives and their use as agonists of atypical beta-adrenoceptors |
| 03/27/2002 | EP0832079B1 Anti-ischaemic hydroxylamine derivatives and pharmaceutical compositions |
| 03/27/2002 | EP0801564B1 Use of nebivolol as an anti-atherogenic |
| 03/27/2002 | EP0782574B1 Bicyclic carboxamides as 5-ht1a receptors ligands |
| 03/27/2002 | EP0734255B1 Novel potassium channel agonist produced from trichoderma virens |
| 03/27/2002 | EP0610336B1 Treatment of neurological conditions by an interleukin-1 inhibiting compound |
| 03/27/2002 | CN1342264A Heart abnormalities in vascular endothelial growth factor B(VEGF-B) deficient animals and methods relating to these heart abnormalities |
| 03/27/2002 | CN1342202A Soluble receptor BR43X2 and methods for using them for therapy |
| 03/27/2002 | CN1342167A Low molecular weight peptide derivatives as inhibitors of laminin/nidogen interaction |
| 03/27/2002 | CN1342166A GLP-1 analogues |
| 03/27/2002 | CN1342165A Neurotrophic growth factor |
| 03/27/2002 | CN1342163A Ketolide antibiotics |
| 03/27/2002 | CN1342162A Substituted 2-acyl-3-(heteroaryl)-imidazo [1,2-a] pyrimidines, and related pharmaceutical compoistions and methods |
| 03/27/2002 | CN1342161A Tricyclic inhibitors of poly(ADP-ribose) polymerases |
| 03/27/2002 | CN1342158A 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists |
| 03/27/2002 | CN1342157A Substituted pyrazoles ASP38 kinase inhibitors |
| 03/27/2002 | CN1342153A Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in production of medicaments |
| 03/27/2002 | CN1342151A 喹啉和喹喔啉化合物 Quinoline and quinoxaline compounds |
| 03/27/2002 | CN1342150A Quinoline and quinoxaline compounds as PDGF-receptor and/or LCK tyrosine kinase inhibitors |
| 03/27/2002 | CN1342139A Serine protease inhibitors |
| 03/27/2002 | CN1342091A Combinations of cardiovascular indications |
| 03/27/2002 | CN1342090A Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular disease |
| 03/27/2002 | CN1342089A Combinations of ileal bile acid transport inhibitors and cholestery ester transfer protein inhibitors for cardiovascular disease |
| 03/27/2002 | CN1342082A Use of tianeptin in production of medicaments to treat neurodegenerative pathologies |
| 03/27/2002 | CN1342080A Use of 5-HT5-ligands in treatment of neurodegenerative and neuropsychiatric disturbances |
| 03/27/2002 | CN1342079A Treatment and prevention of reactive oxygen metablite-mediated cellular damage |
| 03/27/2002 | CN1342077A Inhibition of formation of vascular hyperpermeability |
| 03/27/2002 | CN1342075A Liposome preparations |
| 03/27/2002 | CN1342073A Antioxidant compositions and methods for companion animals |
| 03/27/2002 | CN1342072A Method for preventing or delaying catheter-based revascularization |
| 03/27/2002 | CN1342070A Binding partners for 5-HT5 receptors for treatment of migraine |
| 03/27/2002 | CN1341588A Intermediate product for preparing substituted 2,4-thiazolidine diketone derivative |
| 03/27/2002 | CN1341434A Medicine and health-care product formed from ganglioside and ginkgo leaf extract and their application |
| 03/27/2002 | CN1341431A Capsule for curing apoplexy |
| 03/27/2002 | CN1341421A Shaliwikang soft capsule |
| 03/27/2002 | CN1341420A Medicine formed from ganglioside and erigeron breviscapus extract and health-care product and their application |
| 03/27/2002 | CN1081638C Thienopyrimidines |
| 03/27/2002 | CN1081635C Substituted pyrrolidine-3-Yl-alkyl-piperidines |
| 03/27/2002 | CN1081625C 1-aryl-2-acylamino-ethane compounds and their use as meurokinin especially neurokinin 1 antagonists |
| 03/27/2002 | CN1081465C Method for preparation of Rhodiola rosea injection for treating angina pectoris of coronary heart disease |
| 03/27/2002 | CN1081460C Use of medicine for reducing tissue damage associated with non-cardiac ischemia by aldose reductase inhibitor |
| 03/27/2002 | CN1081442C Shanqi (mountain astragalus root) tea |
| 03/26/2002 | US6362371 β2- adrenergic receptor agonists |
| 03/26/2002 | US6362360 Sensitizers for insulin resistance and associated conditions dyslipidemia and hyperglycemia |
| 03/26/2002 | US6362336 Administering a quinazoline derivative to a warm-blooded animal for producing an antiangiogenic and/or vascular permeability reducing effect |
| 03/26/2002 | US6362322 Conversion of a watson-crick DNA to a hoogsteen-paired duplex |
| 03/26/2002 | US6362236 Statin compound |
| 03/26/2002 | US6362227 Methods for the treatment of tinnitus and other disorders using R(−)ketoptofen |
| 03/26/2002 | US6362223 Cardiovascular disorders |
| 03/26/2002 | US6362211 Polycyclic indanylimidazoles with alpha2 adrenergic activity |
| 03/26/2002 | US6362199 Central nervous system disorders; psychological disorders |
| 03/26/2002 | US6362198 Anticholesterol, antilipemic agent |
| 03/26/2002 | US6362196 Method to treat pain utilizing benzimidazole NMDA/NR2B antagonists |
| 03/26/2002 | US6362195 Inhibitor of nitric oxide synthase; central nervous system disorders |
| 03/26/2002 | US6362190 Administering compounds such as 3-(2-phenylethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylene -carboxamidomethylpyridi nyl)-2-pyrazinone, n'-((1-(aminoiminomethyl)4-piperidinyl) methyl)-n-(3,3-diphenylpropionyl)-l-proline amide |
| 03/26/2002 | US6362186 Aminoalkyl substituted 9H-phridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives |
| 03/26/2002 | US6362182 Hypotensive agents; anticholesterol agents; benign prostatic hypertropic |
| 03/26/2002 | US6362180 Antagonist to corticotropin releasing factor |
| 03/26/2002 | US6362178 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| 03/26/2002 | US6361946 A bone marrow modulating method in mammals by adminstering a polypeptide that binds to at least one endothelial cell surface receptor to modulates myelopoiesis |
| 03/26/2002 | US6361771 Implantable cell culture device comprising semipermeable membrane permitting diffusion of growth factor therethrough, and arpe-19 cells genetically engineered to produce growth factor disposed within semipermeable membrane |
| 03/26/2002 | US6361768 Hydrophilic ampholytic polymer |
| 03/26/2002 | CA2118136C Partially modified and retro-inverted tetrapeptides analogues of c-reactive protein fragments |
| 03/26/2002 | CA2115029C Cyclic urethanes useful as antiarrhythmic and antifibrillatory agents |
| 03/26/2002 | CA2094703C Substituted piperazines as central nervous system agents |
| 03/26/2002 | CA2063030C Substituted n-phenylpiperidines and drugs therefrom |
| 03/26/2002 | CA2032498C Novel 8-substituted-2-aminotetralines |
| 03/21/2002 | WO2002023190A2 Methods and products related to low molecular weight heparin |
| 03/21/2002 | WO2002022818A1 Human and rat pgc-3, ppar-gamma coactivations and splice variants thereof |
| 03/21/2002 | WO2002022801A2 Mammalian receptor genes and uses |
| 03/21/2002 | WO2002022795A2 Isolated human kinase proteins, nucleic acid molecules and uses thereof |
| 03/21/2002 | WO2002022794A2 ENDOTHELIN CONVERTING ENZYMES AND THE AMYLOID βPEPTIDE |
| 03/21/2002 | WO2002022677A2 Variants of allergenic proteins of the group 2 of dermatophagoides |
| 03/21/2002 | WO2002022635A1 Antisense modulation of clusterin expression |
| 03/21/2002 | WO2002022630A1 Purine derivatives |
| 03/21/2002 | WO2002022621A2 INTERPHENYLENE 7-OXABICYCLIC[2.2.1]HEPTANE OXAZOLES AS PROSTAGLANDIN F2a ANTAGONISTS |
| 03/21/2002 | WO2002022620A2 Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin f2$g(a) antagonists |
| 03/21/2002 | WO2002022615A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | WO2002022611A2 Caspase inhibitors and uses thereof |
| 03/21/2002 | WO2002022610A1 Isoxazoles and their use as inhibitors of erk |
| 03/21/2002 | WO2002022608A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022607A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022606A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022605A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022604A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022603A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022602A2 Triazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022601A1 Pyrazole compounds useful as protein kinase inhibitors |